Bempedoic acid (BA) is a novel first-in-class oral lipid-lowering therapy. BA has been approved by the European Medicinal Agency and Food and Drug Administration and has been commercialised throughout Europe since the end of 2020 as an add-on therapy in patients at high/very-high cardiovascular risk that are not at LDL-C goals with current lipid-lowering treatments. Recently, Italian lipid management experts gathered to discuss several open questions on BA characteristics and BArelated practical clinical issues. The panel permitted collection of its opinions in a ten Q&A format. Aim: The aim of this viewpoint is to discuss and answer several open questions on BA characteristics and BA-related practical clinical issues. Data synthesis: The data includes main phase III studies, subanalysis and meta-analysis on BA. Conclusions: The panel permitted collection of its opinions in a ten Q&A format.

Averna M., Bilato C., Sesti G. (2022). Clinical evaluation of bempedoic acid for the treatment of hyperlipidaemia. NMCD. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 32(1), 17-20 [10.1016/j.numecd.2021.09.023].

Clinical evaluation of bempedoic acid for the treatment of hyperlipidaemia

Averna M.
Primo
Conceptualization
;
2022-01-01

Abstract

Bempedoic acid (BA) is a novel first-in-class oral lipid-lowering therapy. BA has been approved by the European Medicinal Agency and Food and Drug Administration and has been commercialised throughout Europe since the end of 2020 as an add-on therapy in patients at high/very-high cardiovascular risk that are not at LDL-C goals with current lipid-lowering treatments. Recently, Italian lipid management experts gathered to discuss several open questions on BA characteristics and BArelated practical clinical issues. The panel permitted collection of its opinions in a ten Q&A format. Aim: The aim of this viewpoint is to discuss and answer several open questions on BA characteristics and BA-related practical clinical issues. Data synthesis: The data includes main phase III studies, subanalysis and meta-analysis on BA. Conclusions: The panel permitted collection of its opinions in a ten Q&A format.
2022
Averna M., Bilato C., Sesti G. (2022). Clinical evaluation of bempedoic acid for the treatment of hyperlipidaemia. NMCD. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 32(1), 17-20 [10.1016/j.numecd.2021.09.023].
File in questo prodotto:
File Dimensione Formato  
Clinical evaluation of bempedoic acid for the treatment of hyperlipidaemia.pdf

accesso aperto

Descrizione: Articolo Principale
Tipologia: Versione Editoriale
Dimensione 228.5 kB
Formato Adobe PDF
228.5 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/532203
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 5
social impact